Clinigen's adjusted gross profit rose by 90% to £102.1m in the year tot he end of June driven by acquisitions and organic growth.
Adjusted EPS rose 25% to 35p (2015: 28p) and net debt decreased £8.1m to £68.1m, after £28.5m spent on acquisitions,
The full year dividend is increased 18% to 4p (2015: 3.4p).
Reported revenue increased by 84%, reported gross profit increased by 79% and reported EPS increased by 83% versus last year, driven by both acquisitions and organic growth.
Key highlights include another outstanding year for Clinical Trial Services (CTS), increasing gross profits by 21% on a pro forma basis, and excellent growth by the newer Specialty Pharmaceutical (SP) products (Ethyol, Cardioxane and Savene), which collectively increased their gross profits by 31%.
Chief executive Peter George said: "The acquisition and integration of Idis and Link Healthcare have transformed the Group over the last 18 months.
"We have achieved our ambition to become the global market leader in the management and supply of both unlicensed and clinical trial medicines, and expanded our global footprint.
"Alongside the significant strategic progress, we have also delivered a strong financial performance with good levels of organic growth combining with the acquisitions to increase adjusted EPS* by 25%.
"The newer products in our Specialty Pharmaceuticals portfolio are making good progress, demonstrating the effectiveness of our revitalisation model and we saw another excellent year in the Clinical Trial Services division."